Sub-Sensitivity to Long-Acting Bronchodilators (LABA)
| 대상 질환 | Asthma |
|---|---|
| 임상 단계 | 단계 해당 없음 |
| 스폰서 | National Jewish Health |
| 상태 | 완료 |
| 참여자 수 | 20 명 |
| 중재(약물) | fluticasone propionate and salmeterol, budesonide and formoterol |
| 시작일 | 2010년 3월 |
| 완료일 | 2013년 9월 |
| 결과 공개일 | 2026년 7월 6일 |
요약
The purpose of this study is to look at whether Advair® and SYMBICORT® have different effects on airway constriction by means of methacholine challenge testing.
Improvement in PC20
| Fluticasone Propionate and Salmeterol | 0.55 PC20 mg/ml |
|---|---|
| Budesonide and Formoterol | 0.41 PC20 mg/ml |
| Fluticasone Propionate and Salmeterol | 0.64 PC20 mg/ml |
| Budesonide and Formoterol | 0.47 PC20 mg/ml |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- A Study of Remote Asthma Management Using an Integrated Artificial Intelligence-assisted E — Mayo Clinic
- Developing a Childhood Asthma Risk Passive Digital Marker — Indiana University
- A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With C — Chiesi Farmaceutici S.p.A.
- A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to — Hoffmann-La Roche
- A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Cortic — Hoffmann-La Roche
- Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Sev — AstraZeneca